Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
adenrx.com

See what CB Insights has to offer

Total Raised

$15M

Investors Count

6

Deal Terms

2

Adenosine Therapeutics Funding, Adenosine Therapeutics Valuation & Adenosine Therapeutics Revenue

5 Fundings

Adenosine Therapeutics's latest funding round was a Acquired for on August 15, 2008.

Adenosine Therapeutics's latest post-money valuation is from August 2008.

Sign up for a free 30-day trial to see Adenosine Therapeutics's valuations in August 2008 and more.

Adenosine Therapeutics's 2004 revenue was $2.4M. Adenosine Therapeutics's most recent revenue is from 2004.

Sign up for a free 30-day trial to see revenue data from 2007 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/15/2008

Acquired

$99M

$0.00B

((9.99x))

FY 1234

6/18/2007

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

9/5/2003

Unattributed VC

$99M

$2.4M

FY 2004

10

5/13/2002

Series A

$99M

$0.00B

((9.99x))

FY 1234

10

Other Investors

$99M

$0.00B

((9.99x))

FY 1234

10

Date

8/15/2008

6/18/2007

9/5/2003

5/13/2002

Round

Acquired

Series C

Unattributed VC

Series A

Other Investors

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$2.4M

FY 2004

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

10

10

10

10

Adenosine Therapeutics Deal Terms

2 Deal Terms

Adenosine Therapeutics's deal structure is available for 2 funding rounds, including their Acquired from August 15, 2008.

Round

Acquired

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series A

Adenosine Therapeutics Investors

6 Investors

Adenosine Therapeutics has 6 investors. PGxHealth invested in Adenosine Therapeutics's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

8/15/2008

8/15/2008

1
Acquired

Connecticut

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporate Venture

Switzerland

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Incubator/Accelerator

Maryland

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Debt & Specialty Finance

California

First funding

8/15/2008

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

8/15/2008

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Corporate Venture

Incubator/Accelerator

Venture Capital

Debt & Specialty Finance

Location

Connecticut

Switzerland

Maryland

California

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.